[go: up one dir, main page]
Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development

Designing Informative Human Pharmacology Studies

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Drug development is, in essence, the answering of scientific questions related to the effects of the intended new medicine. This process starts with preclinical research and proceeds with clinical testing. Especially for innovative drugs, this proceeds along a number of cycles in which the questions are answered by learning from informative studies and subsequent confirmation in more pragmatic studies. Many first-in-human studies and other human pharmacology studies are not designed to be informative but use standard designs and answer generic questions about tolerability and safety. Despite several recent and eloquent pleas for more integrated and quantitative drug development, signs of a strong uptake of this are lacking. In this article, an orderly method for the determination of objective human pharmacology studies is given. The objectives of the study and the expected pharmacology and pharmacokinetics of the compound determine the optimal design; and several general design models and guidelines are given for the design of informative human pharmacology studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References

  1. Zarafonetis CJ, Riley Jr PA, Willis III PW, et al. Clinically significant adverse effects in a phase 1 testing program. Clin Pharmacol Ther 1978; 24(2): 127–32

    PubMed  CAS  Google Scholar 

  2. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 2006; 368(9544): 1387–91

    Article  PubMed  CAS  Google Scholar 

  3. Steinbrook R. Protecting research subjects: the crisis at Johns Hopkins. N Engl J Med 2002; 346(9): 716–20

    Article  PubMed  Google Scholar 

  4. Darragh A, Kenny M, Lambe R, et al. Sudden death of a volunteer. Lancet 1985; 1(8420): 93–4

    Article  PubMed  CAS  Google Scholar 

  5. US FDA. International conference on harmonization; guidance on general considerations for clinical trials [online]. Fed Regist 1997 Dec 17; 62 (242): 66113–9. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/get-doc.cgi?dbname=1997_register&docid=fr17de97-92.pdf [Accessed 2008 Feb 16]

  6. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61(3): 275–91

    Article  PubMed  CAS  Google Scholar 

  7. US FDA Center for Drug Evaluation and Research (CDER). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [online]. Rockville (MD): US FDA CDER, 2005 Jul 21. Available from URL: http://www.fda.gov/cder/guidance/in-dex.htm#Pharmacology/Toxicology [Accessed 2008 Feb 16]

  8. Peck CC, Cross JT. “Getting the dose right”: facts, a blueprint, and encouragements. Clin Pharmacol Ther 2007; 82(1): 12–4

    Article  PubMed  CAS  Google Scholar 

  9. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007; 82(1): 21–32

    Article  PubMed  CAS  Google Scholar 

  10. Expert Group on Phase One Clinical Trials. Final report [online]. Norwich: The Stationary Office, 2006 Dec 7. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicy-AndGuidance/DH_063117 [Accessed 2008 Feb 16]

  11. Cross J, Lee H, Westelinck A, et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. Pharmacoepidemiol Drug Saf 2002; 11(6): 439–46

    Article  PubMed  Google Scholar 

  12. de Visser SJ. A question based approach to drug development [PhD thesis]. Leiden: Leiden University, 2003

  13. van Griensven JM, Jusko WJ, Lemkes HH, et al. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther 1995; 58(6): 631–40

    Article  PubMed  Google Scholar 

  14. Boot JD, de HS, Tarasevych S, et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007; 175(5): 450–7

    Article  PubMed  CAS  Google Scholar 

  15. Hazekamp A, Ruhaak R, Zuurman L, et al. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95(6): 1308–17

    Article  PubMed  CAS  Google Scholar 

  16. Dumont GJ, de Visser SJ, Cohen AF, et al. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 2005; 59(5): 495–510

    Article  PubMed  CAS  Google Scholar 

  17. de Visser SJ, van der Post JP, de Waal PP, et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003; 55(1): 39–50

    Article  PubMed  Google Scholar 

  18. de Visser SJ, van Der PJ, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001; 51(2): 119–32

    PubMed  Google Scholar 

  19. Rijnbeek B, de Visser SJ, Franson KL, et al. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003; 17(2): 196–203

    Article  PubMed  CAS  Google Scholar 

  20. van Der PJ, de Waal PP, de Kam ML, et al. No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity. J Psychopharmacol 2004; 18(1): 109–14

    Article  Google Scholar 

  21. van Der PJ, Noordzij LA, de Kam ML, et al. Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment. J Psychopharmacol 2002; 16(4): 337–43

    Article  Google Scholar 

  22. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327(7425): 1222–5

    Article  PubMed  CAS  Google Scholar 

  23. de Visser SJ, van der Post JP, Nanhekhan L, et al. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. Clin Pharmacol Ther 2002; 72(4): 419–28

    Article  PubMed  Google Scholar 

  24. van der Post JP, de Visser SJ, Schoemaker RC, et al. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3mg sustained release tablet of rilmenidine in hypertensive patients. J Psycho-pharmacol 2004; 18(2): 221–7

    Google Scholar 

  25. Lesko LJ, Atkinson Jr AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347–66

    Article  PubMed  CAS  Google Scholar 

  26. Rolan P, Atkinson Jr AJ, Lesko LJ. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003; 73(4): 284–91

    Article  PubMed  Google Scholar 

  27. US FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products [online]. Rockville (MD): US FDA, 2004 Mar. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Accessed 2008 Feb 16]

  28. van Gerven JM, Uchida E, Uchida N, et al. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol 1998; 38(12): 1129–36

    PubMed  Google Scholar 

  29. Wernevik LC, Nystrom P, Johnsson G, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clin Pharmacokinet 2006; 45(1): 77–84

    Article  PubMed  CAS  Google Scholar 

  30. de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, et al. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception 2003; 68(3): 195–202

    Article  PubMed  Google Scholar 

  31. European Medicines Agency (EMEA). Note for guidance on statistical principles for clinical trials [document reference CPMP/ICH/363/96; online]. London: EMEA, 1998 Sep. Available from URL: http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf [Accessed 2008 Feb 16]

  32. Dingemanse J, van Gerven JM, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44(5): 477–86

    Article  PubMed  CAS  Google Scholar 

  33. Van Gerven JMA, Roncari G, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44(5): 487–93

    Article  PubMed  Google Scholar 

  34. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of the pharmacokinet-ics of therapeutic proteins [document reference CHMP/EWP/89249/2004; online]. London: EMEA, 2007 Jan 24. Available from URL: http://ww-w.emea.europa.eu/pdfs/human/ewp/8924904enfin.pdf [Accessed 2008 Feb 16]

  35. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products [document reference CPMP/EWP/2655/99; online]. London: EMEA, 2000 Jul 27. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/265599en.pdf [Accessed 2008 Feb 16]

  36. Franson KL, Burggraaf J, Bouman-Trio EA, et al. A phase I, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmaco-dynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CNTO528, in healthy male subjects [abstract no. 4283; online]. Blood (ASH Annual Meeting Abstracts) 2005; 106 (11). Available from URL: http://abstracts.hematologylibrary.org/cgi/search?fulltext=franson-&sendit=Enter&volume=106&issue=11&journalcode=ashmtg [Accessed 2008 May 13]

  37. Lammertsma AA. Radioligand studies: imaging and quantitative analysis. Eur Neuropsychopharmacol 2002; 12(6): 513–6

    Article  PubMed  CAS  Google Scholar 

  38. Promasys® clinical trial workflow and data management system [online]. Available from URL: http://www.promasys-software.com [Accessed 2008 Mar 5]

  39. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on requirement for first-in-man clinical trials for potential high-risk medicinal products [document reference EMEA/CHMP/SWP/28367/2007; online]. London: EMEA, 2000 Jun 3. Available from URL: http://www.emea.europa.eu/pdfs/human/swp/2836707en.pdf [Accessed 2008 Feb 16]

  40. Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions: a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007; 81(2): 213–21

    Article  PubMed  CAS  Google Scholar 

  41. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7(3): E503–12

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Centre for Human Drug Research, Zernikedreef 10, Leiden, 2333CL, The Netherlands

    Adam Cohen

Authors
  1. Adam Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam Cohen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, A. Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development. Clin Pharmacokinet 47, 373–381 (2008). https://doi.org/10.2165/00003088-200847060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200847060-00002

Keywords

Search

Navigation